These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 9221830)

  • 1. Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships.
    Connor K; Ramamoorthy K; Moore M; Mustain M; Chen I; Safe S; Zacharewski T; Gillesby B; Joyeux A; Balaguer P
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):111-23. PubMed ID: 9221830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells.
    Weaver CA; Springer PA; Katzenellenbogen BS
    Mol Endocrinol; 1988 Oct; 2(10):936-45. PubMed ID: 2460749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
    Jeng MH; Parker CJ; Jordan VC
    Cancer Res; 1992 Dec; 52(23):6539-46. PubMed ID: 1423300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
    von Angerer E; Birnböck H; Knebel N
    Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-binding activity of polychlorinated hydroxybiphenyls: conformationally restricted structural probes.
    Korach KS; Sarver P; Chae K; McLachlan JA; McKinney JD
    Mol Pharmacol; 1988 Jan; 33(1):120-6. PubMed ID: 3122017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dibenzo[a,g]quinolizin-8-ones: synthesis, estrogen receptor affinities, and cytostatic activity.
    von Angerer S; Brandl G; Mannschreck A; Weimar C; Wiegrebe W
    Anticancer Drug Des; 1992 Oct; 7(5):351-63. PubMed ID: 1388628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polychlorinated biphenyls: correlation between in vivo and in vitro quantitative structure-activity relationships (QSARs).
    Leece B; Denomme MA; Towner R; Li SM; Safe S
    J Toxicol Environ Health; 1985; 16(3-4):379-88. PubMed ID: 3936939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of 6-nitro-1,3,8-trichlorodibenzofuran as a partial estrogen in the female rat uterus.
    Dickerson R; Howie L; Safe S
    Toxicol Appl Pharmacol; 1992 Mar; 113(1):55-63. PubMed ID: 1313194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding characteristics and biological activity of 17 alpha-[125I]iodovinyl-11 beta-methoxyestradiol, an estrogen receptor-binding radiopharmaceutical, in human breast cancer cells (MCF-7).
    McManaway ME; Jagoda EM; Eckelman WC; Larson SM; Francis BE; Gibson RE; Reba RC; Lippman ME
    Cancer Res; 1986 May; 46(5):2386-9. PubMed ID: 3697981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
    Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
    Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element.
    Ernst M; Parker MG; Rodan GA
    Mol Endocrinol; 1991 Nov; 5(11):1597-606. PubMed ID: 1779966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo.
    Robinson SP; Koch R; Jordan VC
    Cancer Res; 1988 Feb; 48(4):784-7. PubMed ID: 3338076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative differences in estrogenic/antiestrogenic effects of clomiphene and zuclomiphene.
    Young RL; Goldzieher JW; Chakraborty PK; Panko WB; Bridges CN
    Int J Fertil; 1991; 36(5):291-5. PubMed ID: 1683658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor stereochemistry: ligand binding orientation and influence on biological activity.
    Chae K; Gibson MK; Korach KS
    Mol Pharmacol; 1991 Nov; 40(5):806-11. PubMed ID: 1944245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
    Watts CK; Sutherland RL
    Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological significance of the interaction of estrogen agonists and antagonists with the estrogen receptor.
    Murphy CS; Jordan VC
    Receptor; 1990-1991 Winter; 1(1-2):65-82. PubMed ID: 2152373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative.
    Botella J; Duc I; Delansorne R; Paris J; Lahlou B
    J Pharmacol Exp Ther; 1989 Feb; 248(2):758-61. PubMed ID: 2918478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
    Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
    Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Phenylbenzo[b]furans: relationship between structure, estrogen receptor affinity and cytostatic activity against mammary tumor cells.
    Erber S; Ringshandl R; von Angerer E
    Anticancer Drug Des; 1991 Nov; 6(5):417-26. PubMed ID: 1764164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.